Related Experiment Videos
Rofecoxib inhibits heterotopic ossification after total hip arthroplasty
Huub J L van der Heide1, Rinco C T Koorevaar, J Albert M Lemmens
1Department of Orthopedics 800, Radboud University Medical Center, P.O. Box 9100, 6500 HB, Nijmegen, The Netherlands.
Introduction:
Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent heterotopic ossification but gastrointestinal complaints are frequently. Selective cyclooxygenase-2 (COX-2) inhibiting NSAID produce less gastrointestinal side effects.
Patients And Methods:
A prospective two-stage study design for phase 2 clinical trials with 42 patients was used to determine if rofecoxib (a COX-2 inhibitor) 50 mg oral for 7 days prevents heterotopic ossification. A cemented primary THA was inserted for osteoarthroses. After 6 months heterotopic bone formation was assessed on AP radiographs using the Brooker classification.
Results:
No heterotopic ossification was found in 81% of the patients, 19% of the patients had Brooker grade 1 ossification.
Conclusion:
Using a two-stage study design for phase 2 clinical trials, a 7-day treatment of a COX-2 inhibitor (rofecoxib) prevents effectively the formation of heterotopic ossification after cemented primary total hip arthroplasty.
Insights
A 7-day course of rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, effectively prevents heterotopic ossification after hip replacement surgery. This finding offers a promising solution for reducing bone formation complications in patients undergoing total hip arthroplasty.
Area of Science:
- Orthopedic Surgery
- Pharmacology
- Clinical Trials
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to prevent heterotopic ossification.
- Gastrointestinal side effects are common with traditional NSAIDs.
- Selective cyclooxygenase-2 (COX-2) inhibitors offer a reduced risk of gastrointestinal complications.
Purpose of the Study:
- To evaluate the efficacy of rofecoxib (a COX-2 inhibitor) in preventing heterotopic ossification.
- To assess the safety and effectiveness of a 7-day rofecoxib regimen.
- To determine the rate of heterotopic ossification after cemented primary total hip arthroplasty.
Main Methods:
- Prospective, two-stage phase 2 clinical trial with 42 patients.
- Patients received 50 mg of oral rofecoxib daily for 7 days.
- Heterotopic ossification was assessed using the Brooker classification on radiographs 6 months post-total hip arthroplasty (THA).
Main Results:
- 81% of patients showed no heterotopic ossification.
- 19% of patients developed Brooker grade 1 ossification.
- No patients experienced higher grades of heterotopic ossification.
Conclusions:
- A 7-day treatment with rofecoxib is effective in preventing heterotopic ossification.
- The COX-2 inhibitor demonstrated a favorable outcome in patients undergoing cemented primary THA.
- This regimen shows potential for clinical use in managing post-arthroplasty heterotopic ossification.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...